Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000821024 | SCV000961763 | uncertain significance | Gastrointestinal stromal tumor; Paragangliomas 3 | 2023-03-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 663196). This variant has not been reported in the literature in individuals affected with SDHC-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 16 of the SDHC protein (p.Ala16Thr). |
| Ambry Genetics | RCV002332706 | SCV002633941 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-10-27 | criteria provided, single submitter | clinical testing | The p.A16T variant (also known as c.46G>A), located in coding exon 2 of the SDHC gene, results from a G to A substitution at nucleotide position 46. The alanine at codon 16 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| All of Us Research Program, |
RCV004002828 | SCV004842664 | uncertain significance | Hereditary pheochromocytoma-paraganglioma | 2024-01-11 | criteria provided, single submitter | clinical testing |